Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC)

Version 5.0

September 2016

The PBAC Guidelines explain in detail how to prepare a submission to list a new medicine or medicinal product on the Pharmaceutical Benefits Schedule (ie for public funding). The guidelines provide detailed instructions on what information is required by the PBAC and the Economic Sub-Committee (ESC) to support a proposed new medicine, and the most appropriate form of clinical evidence and economic evaluation for specific submissions.

Whilst submissions to the PBAC will now need to follow the guidance provided in the PBAC Guidelines version 5.0, the PBAC has approved a transitional arrangement of two PBAC cycles in regard to the structure of submissions. That is, submissions to the PBAC for consideration at either the March or July 2017 PBAC meetings may follow the structure of either version 4.5 or version 5.0 of the Guidelines. Submissions for consideration at the November 2017 meeting must follow the structure of version 5.0 of the PBAC Guidelines.

For information on processes, procedures, timelines and documents required, refer to the Procedure guidance for listing medicines on the Pharmaceutical Benefits Scheme.

Submission structure for submissions requiring evaluation

Section 1 Context Section 2 Clinical evaluation Section 3 Economic evaluation Section 4 Use of the medicine in practice Section 5 Options to present additional relevant information
Section 3A Cost-effectiveness analysis
Section 3B Cost minimisation